<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576029</url>
  </required_header>
  <id_info>
    <org_study_id>CABAZ_L_05933</org_study_id>
    <secondary_id>U1111-1119-8381</secondary_id>
    <nct_id>NCT01576029</nct_id>
  </id_info>
  <brief_title>Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer</brief_title>
  <acronym>SWITCH</acronym>
  <official_title>Phase II Randomized Study of Continuing Treatment With Docetaxel Versus Switching to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in the First Line Treatment of Patients With Castration-Resistant Metastatic Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To compare the continuation of treatment with docetaxel versus switching to cabazitaxel&#xD;
           regarding the time to PSA (Prostatic Specific Antigen) progression (TTP-PSA), in&#xD;
           patients with Castration-Resistant Prostate Cancer (CRPC) that, after four cycles of&#xD;
           docetaxel, have minor PSA response (defined as a reduction between 1% and 49%) or&#xD;
           increase of up to 24% in PSA levels.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  PSA response rate&#xD;
&#xD;
        -  Overall survival (OS)&#xD;
&#xD;
        -  Incidence of Adverse Events&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening: 21days (+7 days) Treatment: until PSA progression Post-treatment Follow-up: 2&#xD;
      years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time to PSA progression</measure>
    <time_frame>up to 60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response rate: Percentage of patients with a decrease of at least 50% in the PSA</measure>
    <time_frame>up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: Median time elapsed between the date of starting treatment until death by any cause</measure>
    <time_frame>up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CABAZITAXEL (XRP6258)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: intravenous</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOCETAXEL (XRP6976)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: intravenous</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Documentation of histological prostate cancer;&#xD;
&#xD;
          -  Patients with metastatic CRPC (Castration-Resistant Metastatic Prostate Cancer) who&#xD;
             progressed with hormone deprivation, including the withdrawal of antiandrogen-class&#xD;
             drugs for at least 4 weeks, and 6 weeks for bicalutamide or if documented that PSA did&#xD;
             not decrease during 3 months of this therapy;&#xD;
&#xD;
          -  Documentation of metastasis by imaging (computerized tomography [CT], magnetic&#xD;
             resonance imaging [MRI] or bone scan), in patients with PSA &lt; 20 ng/mL at the time of&#xD;
             inclusion&#xD;
&#xD;
          -  Provide minor PSA response (characterized by a reduction between 1% and 49%) or&#xD;
             increase up to 24% in PSA levels, in relation to the value measured before starting&#xD;
             docetaxel therapy, measured at least 7 days after the fourth cycle of docetaxel;&#xD;
&#xD;
          -  Patient has received 4 cycles of docetaxel at a dose of 75 mg/m2 ;&#xD;
&#xD;
          -  ECOG performance status of 0 or 1;&#xD;
&#xD;
          -  Marrow, liver and renal function within acceptable values;&#xD;
&#xD;
          -  PSA ≥ 2 ng/mL;&#xD;
&#xD;
          -  Testosterone level ≤ 50 ng/dL (for patients with no prior history of orchiectomy).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior use of chemotherapy, except for docetaxel for four cycles;&#xD;
&#xD;
          -  Documented disease progression during treatment with docetaxel (first 4 cycles);&#xD;
&#xD;
          -  Patients with metastases resulting in neurological damage;&#xD;
&#xD;
          -  Inability to continue receiving gonadotropin-releasing hormone agonists in patients&#xD;
             with no prior history of orchiectomy;&#xD;
&#xD;
          -  Use of recombinant methionyl human granulocyte-colony stimulating factor&#xD;
             non-glycosylated (G-CSF) in the 24 hours preceding baseline;&#xD;
&#xD;
          -  Any other current neoplasia or over the past 5 years, except for basal cell skin&#xD;
             carcinoma or squamous skin cell carcinoma;&#xD;
&#xD;
          -  Known seropositivity for HIV (Human immunodeficiency Virus );&#xD;
&#xD;
          -  Concomitant diseases, such as significant neurological or psychiatric disease;&#xD;
             uncontrolled hypercalcemia or any other serious comorbidity;&#xD;
&#xD;
          -  Hypersensitivity or allergy to any of the study treatments.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 004</name>
      <address>
        <city>Barretos</city>
        <zip>14780-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 008</name>
      <address>
        <city>Brasília</city>
        <zip>70390-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 009</name>
      <address>
        <city>Londrina</city>
        <zip>86015-520</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 003</name>
      <address>
        <city>Mogi das Cruzes</city>
        <zip>0830-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 005</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90840-440</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 006</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 001</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22260-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 007</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>December 23, 2013</last_update_submitted>
  <last_update_submitted_qc>December 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

